Silencing P2X7R Alleviates Diabetic Neuropathic Pain Involving TRPV1 via PKCε/P38MAPK/NF-κB Signaling Pathway in Rats

Lisha Chen1, Hongji Wang1, Juping Xing1

  • 1Department of Physiology, Basic Medical College of Nanchang University, Nanchang 330006, China.

Insights

Targeting the P2X7 receptor and p38 signaling pathway alleviates neuropathic pain in diabetic rats. This intervention reduces TRPV1 expression and inflammatory factors, offering a potential therapeutic strategy for diabetic pain.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Pain Research

Background:

  • Transient receptor potential vanilloid 1 (TRPV1) and P2X7 receptors are implicated in pain signaling.
  • Diabetic neuropathic pain involves complex inflammatory pathways and ion channel interactions.

Purpose of the Study:

  • To investigate the potential link between P2X7 receptor and TRPV1 in diabetic neuropathic pain.
  • To evaluate the therapeutic effects of P2X7 shRNA and p38 inhibitor on pain and inflammation in a rat model.

Main Methods:

  • A type 2 diabetic neuropathic pain rat model was established.
  • Rats received intrathecal injections of P2X7 shRNA or a p38 inhibitor.
  • Dorsal root ganglia were analyzed for protein and gene expression, including inflammatory cytokines and signaling pathways (PKCε/P38 MAPK/NF-κB).

Main Results:

  • Both P2X7 shRNA and p38 inhibitor treatment significantly reduced hyperalgesia and modulated inflammatory factors.
  • TRPV1 expression was significantly decreased by these treatments.
  • The PKCε/P38 MAPK/NF-κB signaling pathway and inflammatory factors in dorsal root ganglia were downregulated.

Conclusions:

  • P2X7 receptor inhibition alleviates nociceptive responses in diabetic neuropathic pain.
  • The mechanism involves the downregulation of TRPV1 expression via the PKCε/P38 MAPK/NF-κB signaling pathway.
  • Targeting P2X7 and p38 pathways presents a promising therapeutic approach for diabetic neuropathic pain.

Related Concept Videos